Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells

PURPOSE: Metastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refractory. Elacestrant, a new generation FDA-approved oral selective estrogen receptor degrader (SERD) and antagonist, has demonstrated efficacy in a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubash, Taronish D., Bardia, Aditya, Chirn, Brian, Reeves, Brittany A., LiCausi, Joseph A., Burr, Risa, Wittner, Ben S., Rai, Sumit, Patel, Hitisha, Bihani, Teeru, Arlt, Heike, Bidard, Francois-Clement, Kaklamani, Virginia G., Aftimos, Philippe, Cortés, Javier, Scartoni, Simona, Fiascarelli, Alessio, Binaschi, Monica, Habboubi, Nassir, Iafrate, A. John, Toner, Mehmet, Haber, Daniel A., Maheswaran, Shyamala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300156/
https://www.ncbi.nlm.nih.gov/pubmed/37318638
http://dx.doi.org/10.1007/s10549-023-06998-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300156/
https://www.ncbi.nlm.nih.gov/pubmed/37318638
http://dx.doi.org/10.1007/s10549-023-06998-w

Ejemplares similares